ASH News Daily 2012 - Tuesday, December 11, 2012 - (Page A-1)
ASH NEWS DAILY
54th Annual Meeting of the American Society of Hematology
®
Read this issue online at
www.hematology.org/ashnewsdaily2012_tuesday
SCHEDULE
Registration
7:00 a.m. – 1:00 p.m.
Hall A2, Level 1, Building A
7:15 – 9:15 a.m.
Special Symposium on the
Basic Science of Hemostasis
and Thrombosis
(invited presentations)
Georgia Ballroom 3, Level 3, Building C
7:30 – 9:00 a.m.
Simultaneous Oral Sessions
Various locations in GWCC
7:30 – 9:00 a.m.
Late-Breaking Abstracts Session
Hall B5, Level 1, Building B
9:30 – 9:45 a.m.
Announcement of the Dameshek
Prize and the Stratton Medal
Hall B5, Level 1, Building B
9:45 – 11:15 a.m.
Presidential Symposium
Hall B5, Level 1, Building B
11:15 – 11:30 a.m.
Business Meeting
Hall B5, Level 1, Building B
12:00 noon – 1:00 p.m.
Best of ASH
Sidney Marcus Auditorium,
Level 4, Building A
Hope I Die Before I Get Old
(Talkin’ About My Regeneration)
them is that Dr. Keating has been far
subtler in moving the field forward
(I don’t recall anyone observing Dr.
Keating windmilling a stethoscope,
but maybe I’m wrong). Continuing
his vision, Dr. Keating will chair the
Presidential
BY MICHAEL R. BISHOP, MD
in many ways he and Pete Townshend
(for those of you who don’t
know,
I
IN THIS SECTION
Stratton and Dameshek
A-3
Thrombosis
A-4
Stem Cells
A-5
Sequencing in MDS
A-7
Pete’s
the
musician who
wrote the song “My Generation”)
share many characteristics in that
they are both visionaries, they continue
to be interested in new ideas,
and both have influenced numerous
peers. The major difference between
’m not sure whether ASH President
Armand Keating, MD, will
appreciate the comparison, but
Symposium
entitled
“Regenerative Medicine” starting
at 9:45 a.m. this morning in Hall B5,
Level 1, Building B.
Regenerative medicine has long
been an interest of Dr. Keating’s,
»»REGENERATION Page A-6
Dr. Timothy
J. Ley opens
his E. Donnall
Thomas
Lecture by paying
tribute to
Thomas, who
passed away
this year. See
page A-2
for a recap
of Dr. Ley’s
presentation.
Effective
Efficacy
BY MARC J KAHN, MD, MBA
he difference between efficacy
and effectiveness in
a clinical trial is how the
efficacy of the trial translates in
effectiveness when the intervention
is applied to real populations
of real patients. Health services
research deals with how patients
get access to practitioners, medications,
and services and what
happens to them as a result of
this care. Health services research
blends the social factors of care
with the scientific factors of clinical
research. Issues of cost, availability,
access, social acceptance
and personal behaviors all affect
the effectiveness of an efficacious
intervention. Health services research
goes beyond the clinical
laboratory and into the home and
community.
Yesterday, several Oral sessions
pertaining to health services
research for issues in the
non-malignant hematology arena
were presented. The results of
the presented abstracts were at
times surprising and may lead to
changes in practice.
Jessica A. Reese, MS, from the
University of Oklahoma,
T
pre-
ASH News Daily author Jose
Bufill, MD, sat down with
the new editors of Blood, Dr.
Bob Löwenberg and Dr. Nancy
Berliner. Turn to page A-6
to read the conversation.
sented abstract 362 detailing morbidity
and mortality following
recovery from an acute episode
of thrombotic thrombocytopenic
purpura (TTP). Although recovery
from an episode of acute TTP
is typically assumed to be complete,
the authors of this study
showed a lower life expectancy
for survivors of TTP and further
demonstrated that hypertension
and diabetes are both previously
unrecognized risk factors
for poor health outcomes in this
population. Another study using
the same database, presented by
Cassandra C. Deford, MA, also
from the University of Oklahoma,
»»EFFICACY Page A-2
http://www.hematology.org/ashnewsdaily2012_tuesday
Table of Contents for the Digital Edition of ASH News Daily 2012 - Tuesday, December 11, 2012
ASH News Daily 2012 - Tuesday, December 11, 2012
https://www.nxtbookmedia.com